Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

NCT05861271 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05861271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05861271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2023
Completion date
July 1, 2028
Enrollment
1,008 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage i